In particular, the recent development and clinical application of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1/ligand-1 (PD-1/PD-L1) immune checkpoint inhibitors once brought a new era of tumor treatment. This evidence concerns the gene CTLA4 and neoplasm.